A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

BACKGROUND: Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clinical development for the treatment of patients with chronic obstructive pulmonary disease (COPD). In a dose-ranging study, nebulized once-daily revefenacin had a long duration of action in patients after 7 days’...

Descripción completa

Detalles Bibliográficos
Autores principales: Pudi, Krishna K., Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Kerwin, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667509/
https://www.ncbi.nlm.nih.gov/pubmed/29096627
http://dx.doi.org/10.1186/s12931-017-0647-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667509/
https://www.ncbi.nlm.nih.gov/pubmed/29096627
http://dx.doi.org/10.1186/s12931-017-0647-1

Ejemplares similares